Due to their recognized functions in controlling LPL activity and the availability of genetic data that supports the proof of concept that decreasing the concentration of these targets is probably going to result in decreased ASCVD risk, ApoC­III and ANGPTL3 (discussed later) are currently the primary targets. This evidence concerns the gene APOC3 and atherosclerosis.